Benefits of weight loss in obese patients with asthma: mechanical or immunological mechanisms?
Completed
- Conditions
- Asthma and obesityRespiratory
- Registration Number
- ISRCTN54432221
- Lead Sponsor
- niversity of Liverpool (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1. Obesity (body mass index more than 30 kg/m^2
2. Age 18 to 65 years
3. Asthma requiring treatment with at least a long-acting inhaled corticosteroid and an inhaled beta agonist
Exclusion Criteria
1. Subjects on long-term oral corticosteroids
2. Diabetes mellitus
3.Pregnancy or breastfeeding
4. History of major eating disorder
5. History of food allergy to any component of Slimfast
6. Major psychiatric disease
7. Current smokers
8. Uncontrolled thyroid disease
9. History of severe cardiac, hepatic or renal disease, malignancy, or any other condition that might, in the opinion of the investigators preclude completion of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected weight loss in the intensive group of 10 to 12 kg (10 - 20% body weight), compared to minimal weight loss in the conventional group. This should result in significant improvements in pulmonary function i.e. reduced bronchoconstriction, reduced peak flow variability and reduced bronchial hyper-reactivity.
- Secondary Outcome Measures
Name Time Method 1. Reduction in systemic inflammation in the intensively treated group<br>2. Reduction in markers of local airway inflammation in the intensively treated group<br>3. Improvement in health status of intensively treated group